At OWKIN, we are dedicated to advancing the state-of-the-art in machine learning for medical research. From finding the next cancer-fighting molecule to tracking tumors, machine learning is an essential tool for pharmacologists, pathologists and many other medical practitioners and researchers. Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters, DREAM Challenge top performers, and publications in ICML, NIPS and other top scientific journals.
Owkin has raised a total of 18.1M$ with funds including Google Ventures and Otium capital, has offices in Paris, New-York, London and Nantes and is now looking for new talents.
OWKIN’s proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes. OWKIN builds scientific collaborations with top-tier medical institutions and partners with leading pharmaceutical companies. OWKIN also develops state-of-the-art federated learning technologies in healthcare to overcome the need to share sensitive medical data, building collective intelligence from distributed data at scale, preserving privacy and security.